Abstract 185P
Background
LIF is an interleukin 6 class cytokine that plays a crucial role in the development of many solid tumors. Herein, we identify the elusive role of LIF in clear cell renal cell carcinoma (ccRCC) and its impact on tumor immune microenvironment.
Methods
The human cancer genome atlas (TCGA) was utilized to obtain ccRCC clinicopathological and expression data. The prognostic utility of LIF expression in ccRCC was evaluated using univariate and multivariate Cox logistic regression analysis. Co-expressed genes were explored using LinkedOmics and their biological roles were identified using gene set enrichment analysis (GSEA) through KEGG pathways terminology. The immune microenvironment was evaluated using Tumor IMmune Estimation Resource (TIMER 2.0). Correlations between LIF expression and immune-related genes were obtained using the Gene Expression Profiling Interactive Analysis (GEPIA).
Results
High LIF expression is associated with shortened overall survival (HR: 1.828, 95% CI: 1.358-2.460, P < .0001) in TCGA ccRCC cohort. Multivariate Cox logistic regression analysis identified LIF expression as an independent prognostic variable (HR: 0.48, 95% CI: 0.303-0.759, P = .002). GSEA showed enrichment in IL-17, TNF, JAK-STAT and NF-kB signaling pathways besides cytokine-cytokine receptor interaction, transcriptional misregulation in cancer, complement and coagulation cascades. LIF expression is positively corelated with immunosuppressive cellular elements including Tregs (ρ = 0.14, Q = 0.012), M2 macrophages (ρ = 0.25, Q < .0001), and myeloidderived suppressor cells (ρ = 0.18, Q value < .001). In addition, LIF corelated significantly with Tregs-related genes including FOXP3 (ρ = 0.28, P < .0001), CCR8 (ρ = 0.23, P < .0001), and TGF-β (ρ = 0.38, P < .0001). M2 macrophages-related genes were also significantly corelated with LIF expression as in CD163 (ρ = 0.30, P < .0001), VSIG4 (ρ = 0.27, P < .0001), and MS4A4A (ρ = 0.24, P < .0001). Immune check points genes were also influenced by LIF expression including CTLA4 (ρ = 0.25, P < .0001) and LAG3 (ρ = 0.21, P < .0001).
Conclusions
LIF upregulation corelates with poor prognosis in ccRCC and induces an immune suppressed microenvironment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1P - Integrated Data Analysis within IMMUcan Identifies Prognostic Features of Early NSCLC
Presenter: Daniel Schulz
Session: Poster Display
3P - Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study
Presenter: Luis Paz-Ares
Session: Poster Display
4P - Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB/IV Non-Small Cell Lung Cancer: relevance of immunosuppressive factors
Presenter: Paulo Santos
Session: Poster Display
5P - Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
Presenter: Giulia Mazzaschi
Session: Poster Display
6P - CD161+CD127+CD8+ T cells as a critical predictor of the efficacy of anti-PD-1 immunotherapy in diabetic patients with non-small cell lung cancer
Presenter: Jingjing Qu
Session: Poster Display
7P - A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer
Presenter: Nuthchaya Mejun
Session: Poster Display
9P - Primary NSCLC patient-derived microtumors (PMTs) for clinical-relvant prediction of immunotherapy efficacy
Presenter: Fabienne Nocera
Session: Poster Display
11P - Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
Presenter: Liang Zheng
Session: Poster Display
12P - Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Melina Peressini Álvarez
Session: Poster Display